An investigation by New Brunswick has found that environmental substances like herbicides and heavy metals are unlikely to be responsible for the neurological symptoms reported by numerous individuals in the province. Dr. Yves Léger, the chief medical officer of health, presented the final report on the probe into 222 cases of “undiagnosed neurological illness” last Friday.
The inquiry was initiated in March to address concerns raised by Dr. Alier Marrero, a neurologist from Moncton, regarding elevated levels of herbicides such as glyphosate and glufosinate, as well as various metals like aluminum, arsenic, lead, and mercury in some patients. Dr. Léger stated during a news conference in Fredericton that the primary findings do not indicate that exposure to specific environmental substances was a probable cause of illness among the majority of the patients studied.
Although the report did not pinpoint the exact cause of the sickness affecting individuals with symptoms ranging from muscle spasms to memory loss, Dr. Léger highlighted that previous reports and scientific studies suggest that the patients likely have a diagnosable illness. Autopsies on nine cases revealed known conditions like Alzheimer’s disease and Creutzfeldt-Jakob disease.
Patient liaison, Sarah Nesbitt, expressed mixed feelings about the report, noting that while some patients were found to have elevated levels of herbicides and heavy metals, many remain uncertain about the cause of their illness and how to address it. Dr. Léger pointed out limitations in the data collected by Marrero, emphasizing the importance of accurate specimen testing and the need for follow-up assessments.
The report proposes three recommendations to support patients in obtaining a second opinion and diagnosis, conducting targeted testing for herbicides and metals, and implementing a formal review process by specialists for cases of undiagnosed neurological illness. Dr. Léger urged the swift implementation of these recommendations.
The provincial government has also requested the Public Health Agency of Canada to evaluate individual patient data for any potential trends or concerns. Patient liaison, Stacie Quigley-Cormier, hopes that the PHAC review will shed light on the reasons for patient clusters and environmental considerations.
Regarding Marrero’s practice and potential disciplinary actions, questions have been redirected to regulatory bodies for further review. The College of Physicians and Surgeons and Vitalité Health Network will assess the report’s recommendations to determine any necessary actions. Patients affected by the mystery illness are expecting ongoing support and guidance throughout the process.